Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy

Michiel Van de Voorde, Charlotte Duchemin, Heinke Reinhard, Laura Lambert, Eric Chevallay, Thomas Schneider, Miranda Van Stenis, Thomas Elias Cocolios, Thomas Cardinaels, Bernard Ponsard, Maarten Ooms, Thierry Stora, Andrew Burgoyne

Research outputpeer-review


Targeted radionuclide therapy (TRNT) has proven to be successful in oncology over the last decade (1–5). In TRNT a radionuclide is linked to a molecule that selectively binds to over-expressed receptors of cancer cells, allowing for a targeted approach in cancer therapy. Accumulation of the radiopharmaceutical in tumor tissue delivers toxic levels of radiation directly to the malicious tumor cells minimizing dose given to healthy tissue.
Original languageEnglish
Article number675221
Pages (from-to)1-9
Number of pages9
JournalFrontiers in Medicine
StatePublished - 19 Jul 2021

Cite this